ArticlePloS one2026
Gastrodin alleviates neuronal damage in epileptic cell models by targeting P2RY12 to inhibit microglial hyperactivation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The potential role of aberrant microglial synaptic pruning in the neurodevelopmental pathogenesis of tourette syndrome.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a chronic neurological disorder characterized by recurrent seizures, with its onset and progression closely linked to neuroinflammation, where abnormal activation and migration of microglia serve as a key pathological process. This study focuses on the regulatory role of gastrodin, the principal active component of the traditional Chinese medicine Gastrodia elata, and its target P2RY12 in chronic epilepsy. Through bioinformatics analysis, P2RY12 was identified as a potential target for Gastrodia elata in treating epilepsy. Molecular docking, Pull-down, and cellular thermal shift assays confirmed that Gastrodin can directly bind to the P2RY12 receptor and inhibit the activation of its downstream RhoA/ROCK signaling pathway. In an in vitro epilepsy model induced by kainic acid (KA), Gastrodin intervention significantly suppressed the migration of microglia toward the injured area and reduced the rearrangement of the F-actin cytoskeleton. Meanwhile, Gastrodin markedly decreased the release of pro-inflammatory cytokines such as TNF-α and IL-1β, alleviated neuronal calcium overload, and inhibited cell apoptosis. Mechanistically, Gastrodin exerts its neuroprotective effects against epilepsy by targeting the P2RY12 receptor to inhibit its mediated chemotactic signaling pathway and inflammatory response, thereby reducing epilepsy-related neuronal damage. Notably, the protective effects of Gastrodin were further enhanced after P2RY12 expression was interfered with, further confirming the critical role of P2RY12 in its neuroprotective action. This study reveals, at the receptor-signaling axis level, the molecular mechanism by which Gastrodin regulates microglial function through P2RY12 to exert anti-epileptic effects, providing not only a solid scientific basis for the clinical application of the traditional Chinese medicine Gastrodia elata but also a novel potential strategy for the treatment of chronic epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.